Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: Harold Engstrom who wrote (9078)	9/8/2006 11:32:29 AM
From: dr.praveen	Respond to of 10345

Thanks for your thoughts. I have seen a few oral MS drugs which have failed. I said that in comparision to the oral MS drugs. No doubt the earlier 0.3mg dose results pale in comparision to the current injectables. I want to watch if this might be an add on therapy to an injectable like BIfn. I can't see this as a monotherapy. My interest to watch this one is to see 1)if the 0.6mg oral dose(double the previous one) will have increased dose efficacy? 2)How will this one fare in combo with B Ifn and other injectables? Regards, Praveen